Lipoprotein(a) Internalization in HepG2 Cells is Regulated by Proprotein Convertase Subtilisin Kexin Type 9 Through the Low-Density Lipoprotein Receptor

被引：0
|
作者：
Romagnuolo, Rocco
Seidah, Nabil G.
Koschinsky, Marlys L.
机构：
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A437
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation
    Weider, Elodie
    Susan-Resiga, Delia
    Essalmani, Rachid
    Hamelin, Josee
    Asselin, Marie-Claude
    Nimesh, Surendra
    Ashraf, Yahya
    Wycoff, Keith L.
    Zhang, Jianbing
    Prat, Annik
    Seidah, Nabil G.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (32) : 16659 - 16671
  • [42] Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
    Park, SW
    Moon, YA
    Horton, JD
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (48) : 50630 - 50638
  • [43] Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
    Kosenko, Tanja
    Golder, Mia
    Leblond, Geoffrey
    Weng, Willy
    Lagace, Thomas A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (12) : 8279 - 8288
  • [44] Circulating Complex of Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 in the Serum Measured by ELISA
    Razova, O. A.
    Afanas'eva, O. I.
    Egiazaryan, M. G.
    Sherstyuk, E. E.
    Klesareva, E. A.
    Pokrovskii, S. N.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 169 (05) : 639 - 643
  • [45] Circulating Complex of Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 in the Serum Measured by ELISA
    O. A. Razova
    O. I. Afanas’eva
    M. G. Egiazaryan
    E. E. Sherstyuk
    E. A. Klesareva
    S. N. Pokrovskii
    Bulletin of Experimental Biology and Medicine, 2020, 169 : 639 - 643
  • [46] LIPOPROTEIN(A) AND PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 LEVELS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
    Galyavich, A. S.
    Gimadeeva, A.
    Galeeva, Z.
    Baleeva, L.
    ATHEROSCLEROSIS, 2020, 315 : E143 - E143
  • [47] Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
    Zaid, Ahmed
    Roubtsova, Anna
    Essalmani, Rachid
    Marcinkiewicz, Jadwiga
    Chamberland, Ann
    Hamelin, Josee
    Tremblay, Michel
    Jacques, Helene
    Jin, Weijun
    Davignon, Jean
    Seidah, Nabil G.
    Prat, Annik
    HEPATOLOGY, 2008, 48 (02) : 646 - 654
  • [48] Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
    Stiekema, Lotte C. A.
    Stroes, Erik S. G.
    Verweij, Simone L.
    Kassahun, Helina
    Chen, Lisa
    Wasserman, Scott M.
    Sabatine, Marc S.
    Mani, Venkatesh
    Fayad, Zahi A.
    EUROPEAN HEART JOURNAL, 2019, 40 (33) : 2775 - +
  • [49] Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children
    Girona, Josefa
    Rodriguez-Borjabad, Celia
    Ibarretxe, Daiana
    Heras, Mercedes
    Amigo, Nuria
    Feliu, Albert
    Masana, Luis
    Plana, Nuria
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (01) : 211 - 218
  • [50] Lipoprotein(a) in atherosclerotic cardiovascular disease and proprotein convertase subtilisin/kexin-type 9 inhibitors
    Lian, Ping-an
    Zhu, Wen-qiang
    Zhao, Wei-xin
    Huang, Piao-piao
    Ran, Juan-li
    Tang, Ya-xin
    Huang, Xian-sheng
    Li, Rong
    CLINICA CHIMICA ACTA, 2025, 565
12345